Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.